NeuroSense Therapeutics Ltd

NASDAQ:NRSN  
1.79
+0.05 (+2.87%)
Earnings Announcements

Neurosense Says Over $10 Mln In Cash And Equivalents At Q2 End

Published: 08/31/2022 13:19 GMT
NeuroSense Therapeutics Ltd (NRSN) - Neurosense Announces Second Quarter 2022 Financial Results and Provides Business Update.
Neurosense Therapeutics Ltd- Well Positioned to Complete Our Phase Iib Study and Report Topline Results in Q2 2023.
Neurosense Therapeutics Ltd- Over $10 Million in Cash and Equivalents on Balance Sheet at End of Q2.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.